Nektar Therapeutics NKTR
Analyst Ratings
- Consensus
- Buy — 8 Buy · 1 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $151.25 (+107.1% upside)
Key Stats
- Today's Range
- $72.05 – $75.75
- 50-Day Range
- $54.13 – $77.23
- 52-Week Range
- $21.02 – $109.00
- Volume
- 828K shs
- Average Volume
- 734K shs
- Market Cap
- $2.57 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.46
- Price / Sales
- 46.17
Short Interest
- Short Interest
- 31.57%
- Days to Cover
- 7.33
Financials (TTM)
- Revenue
- $55.63 million
- Net Income
- $-158,098,000
- Net Margin
- -284.18%
- Return on Equity
- -27.44%
- Debt-to-Equity
- —
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Related Stocks
Compare head-to-head: NKTR vs LLY·NKTR vs JNJ·NKTR vs ABBV·NKTR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.